Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Don t know. Was wondering why it didn t drop when they anounced the rs weeks ago.
Maybe someone or somebody’s opened there email and didn’t like the proxies for the RS.
What's happening today you think? High volume, large drop. Single seller?
In this bear market they have to be prepared for the worst.
No comments about the proposed reverse split?
Link please because I don't see any PR about 25 more scans?
Now they are measuring 25 more scans as significant enough to post PR on it. Fatty liver is exploding and that is all they got???
Insider buying is always nice. Especially when one is the the inventor of the technology.
Coming to a clinician near you soon.
What happened to the milestones over the last four years, Will??
Enough to get past some significant milestones
$11 million of cash left. Burned $3.6 million in Q2. Math question, how many quarters left?
Installed TAEUS system at a fourth clinical evaluation site, in the U.S. Year-to-date, more than 50 TAEUS scans have been performed on study participants, a 25% increase from May 2022, and ENDRA remains on track for at least 200 patients to be scanned by year end. These clinical evaluation sites are being used to generate data to support the commercialization of the TAEUS system, and a subset of the data will be used to support ENDRA's submission of its De Novo request.
Oh brother. 50 scans…
Could be a reason for that…just saying…
On the CC all we may hear is they are on Target to file the DENovo with the FDA in the 3rd qtr. But it would be nice if was by the 15th of this month.
looking forward to the CC on the 15th. Last possible moment for Endra to have one.
Nice upward momentum in the price lately.
In regards to Endra?
NDRA..................................https://stockcharts.com/h-sc/ui?s=NDRA&p=W&b=5&g=0&id=p86431144783
Keep making those new lows?
Why would I tell you that? Why would you even care?
dndodd, please tell me you liquidated your position in NDRA?? You road it all the way down..
Looks like there are now 71 million shares outstanding. They added 20.6 million shares.
As of December 31, 2021, ENDRA had cash and cash equivalents of $9.5 million and 50.4 million fully diluted shares outstanding.
From 8 million shares a few years ago, to 71 million now. Now, that is the Epitome of dilution..
Last trade at .253749, some big wigs buying up ENDRA, no doubt!
$$$NDRA$$$$
Biotech Reverse splits are happening now everywhere like this 25 for 1, so be aware…
$NVCN 1 for 25 reverse split, effective Friday
— TexMex (@TraderTexMex) April 27, 2022
Try not even 2 years at this point right in the throws of COVID lock downs every where. 4/30/2020.
They have had approval in Europe for three years. Francois announce over three years ago that they were actively selling in EU. No sales?
COVID shut downs again for the first two years.
But that excuse is gone this year IMO.
Need to get the trials started in Europe to support sales.
No, Obviously NDRA is not in the XBI as it is too small but it is being lumped in with the rest in the XBI as being no revenue cash burning company. We are beyond Covid excuses. What about the EU, they have EU approval for 2.5 years, but no sales???
NDRA isn't even in the XBI.
So you deny that COVID shut down trials and elective surgeries?
JNJ are not experiencing delays with their approvals. Other small biotechs are making progress with approvals. The reason the XBI has been absolutely destroyed is the XBI is loaded with companies that do not have earnings like NDRA. When you go from a 8 million share float to 60 million share float, with no revenue, there is something amiss, and it is not Covid.
again you appear painfully ignorant on the effects of the Medical business in regards to COVID. No one like s to use it it as an excuse not even Endra but it is a fact.
Probably the main reason the XBI is one of the worst performing sectors in the market.
No medical device company is using that reason anymore.. This was a simple, non complicated review.
Plus, they have had the equivalent approval in the EU for over two years and they have booked zero in revenue. Francois should be fired by the BOD..
Sorry it does COVID has delayed anything Medical and not Covid related 2 years. If you can't see that than you are blind.
Sorry dndodd, Covid had and has nothing to do with their predicament….
Definitely a casualty of COVID but they have to mange out of it. Time will tell if they can.
They had 8 million shares outstanding when I stumbled into them a few years ago, now they will have 60 million shares at $.26
Issue 20.6 million new shares? Is that correct? 40 million existing before offering
Endra Life Sciences (NASDAQ:NDRA) raised $8.7M year-to-date from the sale of common stock through its at the market, or ATM, equity facility.
Pursuant to its ATM equity offering sales agreement with Ascendiant Capital Markets, the company sold ~20.6M shares at an average price of $0.42/share.
If you like high risk situations like Titan why not?
Scooooooooooooooop??
New beginnings for sure. Looking forward to the stated promos and updates. Hold ‘em to it. GL
several significant potential catalysts in that response which are all in the latest Investor presentation available on their website.
Thank you for your email and interest in ENDRA Life Sciences.
As you know, the company does not control the stock’s trading activity, and the best way to address the stock’s performance is for the business to perform. Management is committed to executing its business strategy to commercialize the TAEUS system and looks forward to updating shareholders on material developments as appropriate.
As management stated in the last earnings conference call, there are several key milestones the company is striving to achieve this year including:
Advancing TAEUS through the US regulatory process and submitting a De Novo request,
Demonstrating TAEUS' clinical value by generating additional data with its evaluation sites to support its regulatory submission and commercialization,
Accelerating its commercial channel and marketing activities in line with the reopening of global markets to generate orders for TAEUS in Europe,
Securing additional pharmaceutical and other industry partnerships to expand the opportunity for TAEUS outside the clinical end-user market and
Continuing to strengthen its intellectual property portfolio to protect its proprietary technology, expand its potential area of use and increase out licensing opportunities.
Kind regards,
Yvonne
Followers
|
51
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
1232
|
Created
|
10/24/18
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |